Financial Architects, Inc Acadia Pharmaceuticals Inc Transaction History

Financial Architects, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$36.42 - $57.0 $28,189 - $44,118	-774 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$39.26 - $52.73 $30,387 - $40,813	774 New	774 $38,000
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $15,624 - $18,840	-670 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$16.17 - $27.38 $10,833 - $18,344	670 New	670 $18,000
Q1 2019 May 03, 2019	SELL	$16.17 - $27.38 $14,067 - $23,820	-870 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$14.32 - $22.92 $2,864 - $4,584	200 Added 29.85%	870 $14,000
Q3 2018 Oct 29, 2018	SELL	$13.03 - $21.81 $5,863 - $9,814	-450 Reduced 40.18%	670 $14,000
Q2 2018 Aug 03, 2018	BUY	$15.07 - $22.34 $3,014 - $4,468	200 Added 21.74%	1,120 $17,000
Q1 2018 Apr 23, 2018	BUY	$22.47 - $32.33 $7,864 - $11,315	350 Added 61.4%	920 $21,000
Q4 2017 Feb 12, 2018	BUY	$26.84 - $39.14 $12,078 - $17,613	450 Added 375.0%	570 $17,000
Q3 2017 Nov 01, 2017	BUY	$29.49 - $38.37 $3,538 - $4,604	120	120 $5,000

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.62B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.